Horizon Pharma plc, of Dublin, reported first quarter net sales of $204.7 million. In its orphan drug franchise, sales of urea cycle disorders drug Ravicti (glycerol phenylbutyrate) totaled $37.1 million, while Actimmune (interferon gamma-1b) reached sales of $25.5 million.